RU2471498C2 - Ингибирование ангиогенеза - Google Patents

Ингибирование ангиогенеза Download PDF

Info

Publication number
RU2471498C2
RU2471498C2 RU2010115755/15A RU2010115755A RU2471498C2 RU 2471498 C2 RU2471498 C2 RU 2471498C2 RU 2010115755/15 A RU2010115755/15 A RU 2010115755/15A RU 2010115755 A RU2010115755 A RU 2010115755A RU 2471498 C2 RU2471498 C2 RU 2471498C2
Authority
RU
Russia
Prior art keywords
antibody
vegf
cells
antibodies
tumor
Prior art date
Application number
RU2010115755/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010115755A (ru
Inventor
Наполеон ФЕРРАРА
Фарбод ШОДЖЕЙН
Сюминь У
Цуйлин ЧЖУН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2010115755A publication Critical patent/RU2010115755A/ru
Application granted granted Critical
Publication of RU2471498C2 publication Critical patent/RU2471498C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
RU2010115755/15A 2007-09-21 2008-09-19 Ингибирование ангиогенеза RU2471498C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97438207P 2007-09-21 2007-09-21
US60/974,382 2007-09-21
US8307108P 2008-07-23 2008-07-23
US61/083,071 2008-07-23
PCT/US2008/076954 WO2009039337A2 (en) 2007-09-21 2008-09-19 Inhibition of angiogenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012140185/15A Division RU2012140185A (ru) 2007-09-21 2012-09-19 Ингибирование ангиогенеза

Publications (2)

Publication Number Publication Date
RU2010115755A RU2010115755A (ru) 2011-10-27
RU2471498C2 true RU2471498C2 (ru) 2013-01-10

Family

ID=40030248

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010115755/15A RU2471498C2 (ru) 2007-09-21 2008-09-19 Ингибирование ангиогенеза
RU2012140185/15A RU2012140185A (ru) 2007-09-21 2012-09-19 Ингибирование ангиогенеза

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012140185/15A RU2012140185A (ru) 2007-09-21 2012-09-19 Ингибирование ангиогенеза

Country Status (19)

Country Link
US (1) US9284369B2 (https=)
EP (1) EP2203479B1 (https=)
JP (1) JP5615709B2 (https=)
KR (1) KR101578945B1 (https=)
CN (1) CN102037015B (https=)
AR (1) AR068532A1 (https=)
AU (1) AU2008302214B2 (https=)
CA (1) CA2700276A1 (https=)
CL (1) CL2008002782A1 (https=)
CO (1) CO6270370A2 (https=)
ES (1) ES2568881T3 (https=)
IL (1) IL204502A (https=)
MX (1) MX2010003013A (https=)
NZ (1) NZ584787A (https=)
PE (1) PE20091197A1 (https=)
RU (2) RU2471498C2 (https=)
TW (1) TWI457349B (https=)
WO (1) WO2009039337A2 (https=)
ZA (1) ZA201001868B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311960A3 (en) * 2001-08-29 2011-06-01 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
EP2121924A1 (en) * 2007-03-02 2009-11-25 MDRNA, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CA2777068C (en) 2009-10-14 2020-05-26 Humanigen, Inc. Antibodies to epha3
EP2516465B1 (en) * 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antibodies and uses thereof
EP2536432B1 (en) * 2010-02-19 2018-08-08 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
EP2718326B1 (en) 2011-06-13 2020-08-19 CSL Limited Antibodies against g-csfr and uses thereof
KR20140068877A (ko) * 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013148285A1 (en) * 2012-03-30 2013-10-03 The General Hospital Corporation Methods of inhibiting cell proliferation
TWI498425B (zh) * 2013-01-08 2015-09-01 Nat Univ Tsing Hua 層析濾紙型酵素連結免疫吸附分析法
US20160030558A1 (en) * 2013-03-13 2016-02-04 Health Research, Inc. Enhancement of vaccines
EP3072519B1 (en) * 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
CN104237223B (zh) * 2014-10-08 2017-04-12 江苏奥赛康药业股份有限公司 测定铁‑碳水化合物络合物中不稳定铁含量的方法
CN104587469A (zh) * 2015-01-19 2015-05-06 马洁 G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用
EP3384029B1 (en) * 2015-12-03 2022-01-05 National Health Research Institutes Heterodimeric vascular endothelial growth factor and use thereof
WO2018108862A1 (en) * 2016-12-12 2018-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer
US20210179721A1 (en) * 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
IL325176A (en) 2023-07-05 2026-02-01 CSL Innovation Pty Ltd Methods for treating or preventing a complication of sickle cell disease
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197477C2 (ru) * 1997-12-05 2003-01-27 АСТРАЗЕНЕКА Ю Кей ЛИМИТЕД Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию
WO2004081229A2 (en) * 2003-03-12 2004-09-23 Genentech, Inc. Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2004103274A2 (en) * 2003-05-15 2004-12-02 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311960A3 (en) * 2001-08-29 2011-06-01 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
CN1802169A (zh) * 2003-03-12 2006-07-12 健泰科生物技术公司 Bv8和/或EG－VEGF促进造血的用途
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
ITRM20070182A1 (it) * 2007-04-03 2008-10-04 Univ Roma Antagonisti dei recettori delle prochineticine derivati di essi e loro uso

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197477C2 (ru) * 1997-12-05 2003-01-27 АСТРАЗЕНЕКА Ю Кей ЛИМИТЕД Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию
WO2004081229A2 (en) * 2003-03-12 2004-09-23 Genentech, Inc. Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2004103274A2 (en) * 2003-05-15 2004-12-02 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERENSON JR et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma // J Clin Oncol. 2006 Feb 20; 24(6):937-44. Epub 2006 Jan 17 реферат, он-лайн [Найдено в Интернет на www.pubmed.com 05.05.2011], PMID: 16418495 [PubMed - indexed for MEDLINE]. *
CASANOVAS O et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors // Cancer Cell. 2005 Oct; 8(4):299-3 0950 реферат, он-лайн [Найдено в Интернет на www.pubmed.com 24.10.2011], PMID: 16226705 [PubMed - indexed for MEDLINE]. *
CASANOVAS O et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors // Cancer Cell. 2005 Oct; 8(4):299-3 0950 реферат, он-лайн [Найдено в Интернет на www.pubmed.com 24.10.2011], PMID: 16226705 [PubMed - indexed for MEDLINE]. LECOUTER et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium // Nature 412:877-884 2001. BERENSON JR et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma // J Clin Oncol. 2006 Feb 20; 24(6):937-44. Epub 2006 Jan 17 реферат, он-лайн [Найдено в Интернет на www.pubmed.com 05.05.2011], PMID: 16418495 [PubMed - indexed for MEDLINE]. *
LECOUTER et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium // Nature 412:877-884 2001. *

Also Published As

Publication number Publication date
MX2010003013A (es) 2010-08-02
CN102037015A (zh) 2011-04-27
US9284369B2 (en) 2016-03-15
JP5615709B2 (ja) 2014-10-29
CN102037015B (zh) 2016-02-03
CA2700276A1 (en) 2009-03-26
CO6270370A2 (es) 2011-04-20
ZA201001868B (en) 2011-06-29
JP2010540449A (ja) 2010-12-24
US20100316633A1 (en) 2010-12-16
KR101578945B1 (ko) 2015-12-21
EP2203479A2 (en) 2010-07-07
ES2568881T3 (es) 2016-05-05
WO2009039337A3 (en) 2009-05-14
WO2009039337A2 (en) 2009-03-26
HK1141538A1 (zh) 2010-11-12
AU2008302214A1 (en) 2009-03-26
KR20100075513A (ko) 2010-07-02
RU2010115755A (ru) 2011-10-27
PE20091197A1 (es) 2009-08-14
NZ584787A (en) 2012-12-21
AR068532A1 (es) 2009-11-18
TWI457349B (zh) 2014-10-21
EP2203479B1 (en) 2016-01-27
TW200920750A (en) 2009-05-16
AU2008302214B2 (en) 2012-10-25
IL204502A (en) 2015-05-31
CL2008002782A1 (es) 2009-07-31
RU2012140185A (ru) 2014-03-27

Similar Documents

Publication Publication Date Title
RU2471498C2 (ru) Ингибирование ангиогенеза
EP2361931B1 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20070264193A1 (en) Diagnostics and treatments for tumors
RU2567803C2 (ru) ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
US20150376272A1 (en) Inhibition of angiogenesis in refractory tumors
HK1141538B (en) Inhibition of angiogenesis
HK1194394A (en) Inhibition of angiogenesis in refractory tumors
HK1131628A (en) Diagnostics and treatments for tumors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180920